The evidence for glutathione injections is thin, and the best of it is not favorable. For skin lightening, where IV glutathione has become a prominent cosmetic treatment [2], one small placebo-controlled trial exists, and its result missed statistical significance. For other uses the trials are pilots. The better-documented problem is not the molecule but the ingredient grade used to make some injections, which the FDA has linked to two clusters of reactions.
Glutathione is the most abundant antioxidant the body makes for itself [7]. On this site it sits under the longevity goal.
Skin lightening: the one controlled IV trial
A 2025 systematic review graded the evidence for glutathione as a lightening agent and in melasma [1]. It found five randomized trials and one open study of oral glutathione, at 250 mg to 500 mg a day, that reduced the melanin index compared with placebo. Topical glutathione at 0.5% outperformed 0.1% and placebo.
For intravenous glutathione, the review found only one placebo-controlled study. Responders were 6 of 16, or 37.5% on glutathione against 18.7% on placebo, with p = 0.054. That misses the conventional 0.05 threshold. The review’s conclusion is direct: IV glutathione is contraindicated because of lack of efficacy and side effects.
A 2026 narrative review of the IV route reached the same place [2]. It describes the evidence as limited to modest, varied changes in pigmentation, from small studies with short follow-up. It notes that vitamin C is routinely given alongside, which makes the effect of glutathione itself hard to isolate. It lists hepatotoxicity, hypersensitivity and possible kidney and endocrine effects as emerging concerns.
Other uses: Parkinson’s disease
A randomized, double-blind pilot tested IV glutathione in people with Parkinson’s disease whose symptoms were not controlled by their medicines [3]. Twenty-one were randomized, 11 to glutathione and 10 to placebo, and the glutathione group received 1,400 mg three times a week for 4 weeks. Glutathione was well tolerated. Symptom scores improved 2.8 units more than on placebo during treatment (p = 0.32), a difference that was not significant, and worsened 3.5 units more in the 8 weeks after (p = 0.54).
What the FDA has reported
In February 2019, the FDA warned compounders about glutathione powder repackaged from a manufacturer that marketed it only as a dietary supplement ingredient [4]. Seven patients at one clinic, each given 1,400 mg intravenously, developed symptoms within minutes of infusion, including nausea, vomiting, chills and body aches. One developed low blood pressure and difficulty breathing and was hospitalized. The agency tied the reactions to potentially high levels of endotoxin, a bacterial contaminant.
On August 27, 2026, the FDA reported at least 30 patients with adverse events after IV glutathione compounded by several pharmacies [5]. All had used one lot of glutathione labeled as dietary supplement grade. Reported events included fever, chills, dizziness, and signs of shock and sepsis-like symptoms, some requiring hospitalization. Two pharmacies recalled products over elevated endotoxin. The FDA reminds compounders that supplement-grade ingredients are not appropriate for injectable drugs.
Injection versus mouth
The case for injection usually rests on the idea that oral glutathione is destroyed in the gut. A 6-month randomized trial in 54 non-smoking adults tested that [7]. At 1,000 mg a day, glutathione stores rose 30% to 35% in red cells, plasma and lymphocytes, and 260% in cheek cells, and returned to baseline after a month off. That does not show oral glutathione does anything clinical, but it weakens the claim that only an injection raises levels.
Regulatory status is set by the FDA’s 503A list, updated May 14, 2026, which places glutathione in Category 1, bulk substances under evaluation [8]. Its use on the skin, beside other peptides, is covered in which peptides for skin have human trials. A related longevity compound delivered through the nose is covered in what is known about NAD nasal spray. Where to read the grading rules behind these summaries: the methodology.